NCT04415320View on ClinicalTrials.gov

X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

PHASE2UnknownINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 21, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

June 30, 2021

Conditions
Lung Cancer, Nonsmall CellBrain Metastases
Interventions
DRUG

X-396(Ensartinib)

All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
collaborator

Fudan University

OTHER

lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY